In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dealmaking When Pharma's the Only Game in Town

Executive Summary

With no public market to provide competition, the theory among biotech's optimists was that Big Pharma would step in and buy lots of bargains. But cheap prices and easy availability haven't increased drug company appetites: They will only buy what they really want. Deal volumes, both for M&A and alliances, are falling, while Big Pharma has learned to put more of the risk back on biotech. What will change this dynamic, putting more bargaining into biotech hands, is the revival of the public market - and there are hints that such a revival may be on the way.

You may also be interested in...

Financings Of The Fortnight: Is Buoyant Biotech IPO Scene Altering Private Biotech M&A Trends?

When the IPO spigot runs dry, there’s M&A aplenty, and when the IPO wine is flowing, M&A slows down, right? FOTF tackles some conventional wisdom; plus deals from Acadia, Neurocrine, Aquinox, and Human Longevity.

Natural Products: Back In Vogue?

Several small biotechs are heading back to nature, spotting promising drug targets in exotic plants, sea creatures, and venomous animals, even as Big Pharma and venture capital remain skeptical of the approach.

Biotech's Role In Rebuilding Big Pharma's Neglected Antibiotic Pipeline

Antibiotic resistance has become a key market opportunity, but Big Pharma is poorly positioned to take advantage. Having all but abandoned antibiotic drug development at least a decade ago to smaller companies able to take on the risk, major drugmakers now look to those firms as a resource to revive their pipelines. But there may not be much to choose from.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts